Background
Methods
Model overview
Data sources
Population
Disease progression and treatment effects
Outcome | Donepezil | Memantine | Difference |
---|---|---|---|
MMSE (0-30) | 1.16 | 0.48 | -0.68 |
NPI (0-144) | -2.40 | -2.76 | -0.36 |
Function (0-100) | -4.44 | -2.35 | 2.09 |
Relative Risk of Drop-Out | 1.18 | 0.66 | 0.62 |
Persistence
Months 0-3 | Months 0-6 | Months 6-12 | Annual Risk After 12 Months | |
---|---|---|---|---|
Donepezil | 5.1% | 5.1% | 10.2% | 10.3% |
Memantine | 3.1% | 3.1% | 6.3% | 6.3% |
Mortality
Medical costs
Care costs by disease severity (MMSE) | Monthly costs | Source | |
---|---|---|---|
Mild | ≥ 25 | €184 | Adapted from Teipel et al. 2007[18] |
≥ 20 - < 25 | €593 | ||
Moderate | ≥ 15 - < 20 | €1,275 | |
≥ 10 - < 15 | €1,958 | ||
Severe | < 10 | €2,981 | |
Drugs
|
Treatment costs
per day**
|
Source
| |
Donepezil 10 mg | €4.20 | Rote Liste® 2008[49] | |
Memantine 20 mg | €3.83 | Rote Liste® 2008[49] | |
Outpatient treatment monitoring
|
Costs per quarter
|
Source
| |
GP visit, geriatric assessment, MMSE test (one per quarter) | €53.47* | EBM2008[46] |
Caregiver time costs
Location of care
Health utilities
Analyses
Results
Patients with MMSE ≥ 10 and ≤ 26 versus untreated patients | Untreated | Donepezil | Net difference |
---|---|---|---|
Survival (undiscounted, in years) | 4,870 | 4,870 | 0,000 |
Drug Costs | € 0 | € 4,625 | €4,625 |
Total Non-Drug Direct Costs | €126,863 | €115,231 | -€11,632 |
Total Direct Costs | €126,863 | €119,856 | -€7,007 |
Indirect Costs | €87,138 | €84,253 | -€2,885 |
Total Costs
|
€214,001
|
€204,108
|
-€9,893
|
Years with MMSE > 10 | 1,972 | 2,435 | 0,463 |
Years with NPI < 28 | 2,680 | 2,794 | 0,114 |
Years with ADL < 50 | 1,896 | 2,036 | 0,140 |
Years with IADL < 50 | 0,241 | 0,303 | 0,062 |
Years in Institution | 1,663 | 1,457 | -0,206 |
Total Care Time (Years) | 1,908 | 1,845 | -0,063 |
QALYs (Patient) | 1,659 | 1,790 | 0,131 |
QALYs (Caregiver) | 3,272 | 3,287 | 0,014 |
QALYS (Patient + Caregiver)
|
4,931
|
5,077
|
0,146
|
Health Care Direct Cost/QALY (Patient + Caregiver) | Dominant | ||
Societal Total Cost/QALY (Patient +Caregiver) | Dominant | ||
Patients with MMSE ≥ 10 and < 20 versus memantine
|
Memantine
|
Donepezil
|
Net difference
|
Survival (undiscounted, in years) | 4,909 | 4,909 | 0,000 |
Drug Costs | €4,972 | €4,696 | -€276 |
Total Non-Drug Direct Costs | €129,702 | €128,019 | -€1,684 |
Total Direct Costs | €134,674 | €132,715 | -€1,960 |
Indirect Costs | €89,572 | €88,707 | -€ 865 |
Total Costs
|
€224,246
|
€221,422
|
-€2,825
|
Years with MMSE > 10 | 2,023 | 2,801 | 0,058 |
Years with NPI < 28 | 2,808 | 2,751 | -0,058 |
Years with ADL < 50 | 1,772 | 1,835 | 0,062 |
Years with IADL < 50 | 0,186 | 0,209 | 0,023 |
Years in Institution | 1,702 | 1,673 | -0,028 |
Total Care Time (Years) | 1,961 | 1,942 | -0,019 |
QALYs (Patient) | 1,663 | 1,677 | 0,014 |
QALYs (Caregiver) | 3,276 | 3,279 | 0,003 |
QALYS (Patient + Caregiver)
|
4,939
|
4,956
|
0,017
|
Health Care Direct Cost/QALY (Patient + Caregiver) | Dominant | ||
Societal Total Cost/QALY (Patient +Caregiver) | Dominant |
Analysis | QALYs | Total costs | Cost per QALY | QALYs | Total costs | Cost per QALY |
---|---|---|---|---|---|---|
Patients with MMSE 10-26: donepezil versus no treatment | Patients with MMSE 10-20: donepezil versus memantine | |||||
Base Case
|
0.146
|
-€9,893
|
Dominant
|
0.017
|
-€2,825
|
Dominant
|
Caregiver Time Effects of Disease Severity ↓ 25%†
| 0.146 | -€9,171 | Dominant | 0.017 | -€2,608 | Dominant |
Patient Care Cost ↓ 25%‡
| 0.146 | -€6,911 | Dominant | 0.017 | -€2,417 | Dominant |
Patients institutionalized ↓ 25% | 0.135 | -€9,893 | Dominant | 0.015 | -€2,825 | Dominant |
Patient Utility Effects of Disease Severity ↓ 25% | 0.124 | -€9,893 | Dominant | 0.015 | -€2,825 | Dominant |
Stop Treatment if MMSE < 10 | 0.132 | -€11,006 | Dominant | 0.018 | -€2,279 | Dominant |
Stop Treatment if MMSE Deteriorates on any Scale after 6 Months | 0.140 | -€9,691 | Dominant | 0.054 | -€4,578 | Dominant |
5 Year Time Horizon | 0.140 | -€10,172 | Dominant | 0,016 | -€2,578 | Dominant |
Treatment Effects ↓ 25%†
| 0.107 | -€5,930 | Dominant | 0.023 | -€3,379 | Dominant |
No Discontinuation | 0.204 | -€13,215 | Dominant | 0.041 | -€4,301 | Dominant |
Double Discontinuation | 0.106 | -€7,412 | Dominant | 0.003 | -€1,760 | Dominant |
Treatment Duration 5 Years | 0.140 | -€10,171 | Dominant | 0.016 | -€2,580 | Dominant |
Treatment Duration 1 Year | 0.042 | -€2,704 | Dominant | 0.008 | -€991 | Dominant |
Alternative caregiver time effect (German data)[47] | 0.146 | -€16,677 | Dominant | 0.017 | -€3,288 | Dominant |
Alternate disease severity definition based on German convention MMSE ranges * | 0.151 | -€9,486 | Dominant | 0.019 | -€3,448 | Dominant |